Under settlement, FDA has to pre-approve Merck ads

One feature of Merck and Schering-Plough's settlement with 35 state attorneys general is a provision requiring the companies to get FDA to bless all its DTC advertisements--not just those for Vytorin, the cholesterol med that prompted the probe--before airing or publishing them. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.